In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Atreca (BCEL – Research Report), with a price target of $25.00. The company's shares closed last Wednesday at $1.59, close to its 52-week low of $1.52. According to TipRanks.com, Pantginis ' ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -30.6% and a 18.2% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Bioline RX Ltd Sponsored ADR, Applied Genetic Technologies, and Lineage Cell Therapeutics. Atreca has an analyst consensus of Strong Buy, with a price target consensus of $17.40, a 929.6% upside from current levels.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-atrecas-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From May 2023 to Jun 2023 Click Here for more Atreca Charts.
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Jun 2022 to Jun 2023 Click Here for more Atreca Charts.